13F-HR filed by Trails Edge Capital Partners, LP
Trails Edge Capital Partners, LP filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 16:23:29 UTC, with 38 holding rows worth $695,902,449.
- Accession
- 0002077247-26-000005
- Filer
- CIK 2077247
- Filed
- 2026-11-16
- Accepted by EDGAR
- Ingested
- Source
- EDGAR live feed
13F report for Q3 2026
A holdings report, 38 entries on the cover page, a total value of $695,902,449 stated on the cover page (in dollars after the unit check, H1), rows summing to $695,902,449 with VALUE read as dollars as filed, 13F file number 028-26566. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| LB PHARMACEUTICALS INC | 50180M108 | COMMON STOCK | 1,149,240 | $44,107,831 | dollars as filed | |
| BIOMARIN PHARMACEUTICAL INC | 09061G101 | COM | 667,000 | $40,020,000 | dollars as filed | |
| NURIX THERAPEUTICS INC | 67080M103 | COMMON STOCK | 1,573,220 | $37,301,046 | dollars as filed | |
| Obsidian Therapeutics, Inc. | 67448A106 | Common Stock, $0.0001 par value per share | 2,495,660 | $34,265,412 | dollars as filed | |
| IMMUNOCORE HLDGS PLC ADS | 45258D105 | ADR | 1,063,234 | $32,205,358 | dollars as filed | |
| 4D MOLECULAR THERAPEUTICS INC COM | 35104E100 | Stock | 2,227,917 | $31,881,492 | dollars as filed | |
| DESIGN THERAPEUTICS INC | 25056L103 | COM | 2,500,000 | $31,425,000 | dollars as filed | |
| CYTOKINETICS INC | 23282W605 | COM NEW | 470,000 | $30,977,700 | dollars as filed | |
| FIRST TRACKS BIOTHERAPEUTICS | 337185102 | ORD SHS *A* | 814,000 | $28,848,160 | dollars as filed | |
| FAETH THERAPEUTICS INC | 81728A207 | COM NEW | 941,689 | $28,005,830 | dollars as filed | |
| TANGO THERAPEUTICS INC | 87583X109 | COM | 1,100,000 | $27,445,000 | dollars as filed | |
| NEUROGENE INC | 64135M105 | COMMON STOCK | 964,885 | $26,843,100 | dollars as filed | |
| CELLDEX THERAPEUTICS INC NEW | 15117B202 | COM NEW | 765,000 | $24,793,650 | dollars as filed | |
| AVALO THERAPEUTICS INC | 05338F306 | COMMON STOCK | 1,500,000 | $22,995,000 | dollars as filed | |
| CONTINEUM THERAPEUTICS INC CL A | 21217B100 | Stock | 1,693,694 | $22,729,374 | dollars as filed | |
| TYRA BIOSCIENCES INC | 90240B106 | COMMON STOCK | 1,000,000 | $21,870,000 | dollars as filed | |
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 1,680,000 | $19,656,000 | dollars as filed | |
| INHIBIKASE THERAPEUTICS INC | 45719W205 | COMMON STOCK | 9,110,112 | $18,721,280 | dollars as filed | |
| INHIBRX BIOSCIENCES INC | 45720N103 | COM | 170,000 | $17,013,600 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 400,000 | $14,876,000 | dollars as filed | |
| CAMP4 THERAPEUTICS CORP | 13463J101 | COM | 3,625,576 | $14,647,327 | dollars as filed | |
| ALTIMMUNE INC | 02155H200 | COM NEW | 4,230,000 | $12,097,800 | dollars as filed | |
| OPUS GENETICS INC | 67577R102 | COMMON STOCK | 2,411,657 | $11,672,420 | dollars as filed | |
| KAILERA THERAPEUTICS INC | 482931102 | COMMON STOCK | 942,953 | $10,768,523 | dollars as filed | |
| SOL-GEL TECHNOLOGIES LTD | M8694L137 | SHS NEW | 139,445 | $10,357,974 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 2,657,997 | $9,808,009 | dollars as filed | |
| ENTRADA THERAPEUTICS INC COM | 29384C108 | Stock | 1,428,440 | $9,070,594 | dollars as filed | |
| AURA BIOSCIENCES INC | 05153U107 | COMMON STOCK | 1,443,333 | $9,064,131 | dollars as filed | |
| Research Alliance Corp Iii Ord Shs Cl A | G75226103 | Common Stock | 822,500 | $8,907,676 | dollars as filed | |
| X4 PHARMACEUTICALS INC | 98420X202 | COMMON STOCK | 2,571,478 | $7,457,287 | dollars as filed | |
| CENTURY THERAPEUTICS INC | 15673T100 | COM | 4,134,969 | $7,070,797 | dollars as filed | |
| PROMIS NEUROSCIENCES INC | 74346M505 | COM SHS | 557,103 | $6,044,568 | dollars as filed | |
| RESEARCH ALLIANCE CORP IV | G75228109 | CL A ORD SHS | 500,000 | $6,000,000 | dollars as filed | |
| IMAGENEBIO INC | 45175G207 | CMN | 1,094,045 | $5,010,726 | dollars as filed | |
| MINERVA NEUROSCIENCES INC | 603380205 | COM NEW | 1,419,000 | $4,753,650 | dollars as filed | |
| TCGX ACQUISITION CORP | G8708J109 | COM | 250,000 | $3,127,500 | dollars as filed | |
| VTV THERAPEUTICS INC | 918385204 | CL A NEW | 76,989 | $2,374,341 | dollars as filed | |
| ONKURE THERAPEUTICS INC | 68277Q105 | COM CL A | 619,557 | $1,688,293 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0002077247-26-000005 | this filing | 2026-11-16 |